191 related articles for article (PubMed ID: 33309781)
1. Splicing factors: Insights into their regulatory network in alternative splicing in cancer.
Du JX; Zhu GQ; Cai JL; Wang B; Luo YH; Chen C; Cai CZ; Zhang SJ; Zhou J; Fan J; Zhu W; Dai Z
Cancer Lett; 2021 Mar; 501():83-104. PubMed ID: 33309781
[TBL] [Abstract][Full Text] [Related]
2. Development and validation of AI/ML derived splice-switching oligonucleotides.
Fronk AD; Manzanares MA; Zheng P; Geier A; Anderson K; Stanton S; Zumrut H; Gera S; Munch R; Frederick V; Dhingra P; Arun G; Akerman M
Mol Syst Biol; 2024 Jun; 20(6):676-701. PubMed ID: 38664594
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Applications of Targeted Alternative Splicing to Cancer Treatment.
Lin JC
Int J Mol Sci; 2017 Dec; 19(1):. PubMed ID: 29283381
[TBL] [Abstract][Full Text] [Related]
4. Splicing-factor alterations in cancers.
Anczuków O; Krainer AR
RNA; 2016 Sep; 22(9):1285-301. PubMed ID: 27530828
[TBL] [Abstract][Full Text] [Related]
5. Alternative splicing modulates cancer aggressiveness: role in EMT/metastasis and chemoresistance.
Roy Burman D; Das S; Das C; Bhattacharya R
Mol Biol Rep; 2021 Jan; 48(1):897-914. PubMed ID: 33400075
[TBL] [Abstract][Full Text] [Related]
6. Alternative-splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics.
Urbanski LM; Leclair N; Anczuków O
Wiley Interdiscip Rev RNA; 2018 Jul; 9(4):e1476. PubMed ID: 29693319
[TBL] [Abstract][Full Text] [Related]
7. Alternative splicing and cancer: a systematic review.
Zhang Y; Qian J; Gu C; Yang Y
Signal Transduct Target Ther; 2021 Feb; 6(1):78. PubMed ID: 33623018
[TBL] [Abstract][Full Text] [Related]
8. Upstream analysis of alternative splicing: a review of computational approaches to predict context-dependent splicing factors.
Carazo F; Romero JP; Rubio A
Brief Bioinform; 2019 Jul; 20(4):1358-1375. PubMed ID: 29390045
[TBL] [Abstract][Full Text] [Related]
9. Alternative Splicing: Recent Insights into Mechanisms and Functional Roles.
Ghigna C; Paronetto MP
Cells; 2020 Oct; 9(10):. PubMed ID: 33092102
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic targeting of splicing in cancer.
Lee SC; Abdel-Wahab O
Nat Med; 2016 Sep; 22(9):976-86. PubMed ID: 27603132
[TBL] [Abstract][Full Text] [Related]
11. Genome-Wide Analysis of Prognostic Alternative Splicing Signature and Splicing Factors in Lung Adenocarcinoma.
Chang YS; Tu SJ; Chiang HS; Yen JC; Lee YT; Fang HY; Chang JG
Genes (Basel); 2020 Oct; 11(11):. PubMed ID: 33142748
[TBL] [Abstract][Full Text] [Related]
12. Systematic Profile Analysis of Prognostic Alternative Messenger RNA Splicing Signatures and Splicing Factors in Head and Neck Squamous Cell Carcinoma.
Xing L; Zhang X; Tong D
DNA Cell Biol; 2019 Jul; 38(7):627-638. PubMed ID: 31025877
[TBL] [Abstract][Full Text] [Related]
13. Targeting splicing factors for cancer therapy.
Bashari A; Siegfried Z; Karni R
RNA; 2023 Apr; 29(4):506-515. PubMed ID: 36697261
[TBL] [Abstract][Full Text] [Related]
14. Co-regulated gene expression of splicing factors as drivers of cancer progression.
Koedoot E; Smid M; Foekens JA; Martens JWM; Le Dévédec SE; van de Water B
Sci Rep; 2019 Apr; 9(1):5484. PubMed ID: 30940821
[TBL] [Abstract][Full Text] [Related]
15. The combinatorial control of alternative splicing in C. elegans.
Tan JH; Fraser AG
PLoS Genet; 2017 Nov; 13(11):e1007033. PubMed ID: 29121637
[TBL] [Abstract][Full Text] [Related]
16. Specific inhibition of splicing factor activity by decoy RNA oligonucleotides.
Denichenko P; Mogilevsky M; Cléry A; Welte T; Biran J; Shimshon O; Barnabas GD; Danan-Gotthold M; Kumar S; Yavin E; Levanon EY; Allain FH; Geiger T; Levkowitz G; Karni R
Nat Commun; 2019 Apr; 10(1):1590. PubMed ID: 30962446
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic Targeting of Alternative RNA Splicing in Gastrointestinal Malignancies and Other Cancers.
Sahin I; George A; Seyhan AA
Int J Mol Sci; 2021 Oct; 22(21):. PubMed ID: 34769221
[TBL] [Abstract][Full Text] [Related]
18. Alternative RNA splicing defects in pediatric cancers: new insights in tumorigenesis and potential therapeutic vulnerabilities.
Venkataramany AS; Schieffer KM; Lee K; Cottrell CE; Wang PY; Mardis ER; Cripe TP; Chandler DS
Ann Oncol; 2022 Jun; 33(6):578-592. PubMed ID: 35339647
[TBL] [Abstract][Full Text] [Related]
19. Targeting Splicing in Prostate Cancer.
Antonopoulou E; Ladomery M
Int J Mol Sci; 2018 Apr; 19(5):. PubMed ID: 29693622
[TBL] [Abstract][Full Text] [Related]
20. RNA components of the spliceosome regulate tissue- and cancer-specific alternative splicing.
Dvinge H; Guenthoer J; Porter PL; Bradley RK
Genome Res; 2019 Oct; 29(10):1591-1604. PubMed ID: 31434678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
